A5058967910- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Head and Neck Cancer Studies
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Immunotherapy and Immune Responses
- Cancer therapeutics and mechanisms
- Peptidase Inhibition and Analysis
- Kruppel-like factors research
- Melanoma and MAPK Pathways
- Economic and Financial Impacts of Cancer
- HER2/EGFR in Cancer Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer-related gene regulation
- Genetic factors in colorectal cancer
- RNA modifications and cancer
- Hematopoietic Stem Cell Transplantation
- Chronic Myeloid Leukemia Treatments
- Viral-associated cancers and disorders
- Angiogenesis and VEGF in Cancer
Oncology Institute of Hope and Innovation
2025
Universidade Estadual de Campinas (UNICAMP)
2021-2025
Florida Atlantic University
2014-2024
Universidade Estadual Paulista (Unesp)
2024
Aventura Hospital and Medical Center
2024
Genesis HealthCare
2023
Fundação de Apoio à Universidade Federal de São Paulo
2023
Hematology Oncology Consultants
2021
Lynn University
2013-2020
21st Century Oncology (United States)
2019-2020
PURPOSE To provide evidence-based recommendations to practicing clinicians on radiographic imaging and biomarker surveillance strategies after definitive curative-intent therapy in patients with stage I-III non–small-cell lung cancer (NSCLC) SCLC. METHODS ASCO convened an Expert Panel of medical oncology, thoracic surgery, radiation pulmonary, radiology, primary care, advocacy experts conduct a literature search, which included systematic reviews, meta-analyses, randomized controlled trials,...
We assessed the Aurora A kinase inhibitor, alisertib, plus paclitaxel (henceforth referred to as alisertib/paclitaxel) second-line treatment for SCLC.In this double-blind study, patients with relapsed or refractory SCLC were stratified by relapse type (sensitive versus resistant refractory) and brain metastases randomized 1:1 alisertib/paclitaxel placebo placebo/paclitaxel) in 28-day cycles. The primary end point was progression-free survival (PFS). Associations of c-Myc expression tumor...
Este artigo analisa como o tratamento dado à temática das relações étnico-raciais nos Projetos Políticos Pedagógicos (PPPs) dos municípios de Sumaré e Hortolândia está alinhado ou não às propostas do Currículo Paulista para a etapa da Educação Básica. Foram selecionados 35 Diretoria Ensino Sumaré, quais quatro são aqui analisados documentalmente, com vistas a: identificar frequência em que apareciam os termos estratégicos busca utilizados (exemplos: “raça”, “etnia” “relações...
Rituximab, a chimeric monoclonal anti-CD20 antibody, has shown activity in several autoimmune disorders. We describe case of 52 years old female who was diagnosed with idiopathic thrombocytopenic purpura and concomitant hepatitis (AIH), both non-responsive to steroids. She subsequently treated rituximab, which resulted rapid increase her platelet count an unexpected normalization hepatic biochemical tests. Both tests remained normal for over 5 months. In this case, rituximab showed...
Abstract Because of the refractory nature mutant KRAS lung adenocarcinoma (LUAD) to current therapies, identification new molecular targets is essential. Genes with a prognostic role in LUAD have proven be potential for therapeutic development. Here we determine clinical, functional, and mechanistic inhibitor differentiation-1 (Id1) LUAD. Analysis cohorts from TCGA SPORE showed that high expression Id1 was marker poor survival patients harboring mutant, but not wild-type KRAS. Abrogation...
Despite the significant progress in treatment of unresectable or metastatic BRAF V600-mutant melanoma, there remains two primary options: targeted therapy and immunotherapy. Targeted immunotherapy alone is associated with efficacy limitations including limited to select patient subsets. With separate mechanisms action different response patterns, combination agents treat patients melanoma may further improve outcomes. Current guidelines recommend alone, immunotherapy, The randomized,...